Scientific Industries announced that it will file its Form 10‑Q and issue a release detailing its third‑quarter fiscal 2025 financial results, which cover the period ending September 30, 2025. The company will host an investor conference call on November 20, 2025, at 11:00 a.m. Eastern Time, with a replay available through November 27, 2025 on its Investor Relations website and via live webcast.
The company’s most recent quarter, Q2 2025, reported net revenues of $2.3 million, down from $2.6 million in the same period a year earlier, and a gross margin of 43.8% versus 48.8% year‑over‑year. The decline was driven by lower sales of Genie products in the Benchtop Laboratory Equipment segment, while the Bioprocessing Systems segment saw a modest increase in Torbal sales. These figures illustrate the impact of the company’s divestiture of legacy product lines and the cost pressures associated with higher material and fixed‑overhead expenses.
Segment performance in the prior year’s third quarter provides additional context: Benchtop Laboratory Equipment Operations net sales rose 7.1% to $2.769 million, and Bioprocessing Systems Operations net sales increased 6.6%. The growth in the bioprocessing segment reflects the company’s strategic focus on high‑margin, high‑growth markets, while the laboratory equipment segment remains sensitive to commodity pricing and competitive dynamics.
CEO Helena Santos highlighted the progress of the company’s strategic transformation during the Q2 2025 earnings call. She noted the divestiture of the Genie business and the continued development of the VIVID pill‑counting system, underscoring a shift toward AI‑powered platforms and bioprocessing technologies. The commentary signals management’s confidence that the new product pipeline will drive future revenue and margin expansion.
The upcoming Q3 2025 results will be critical to assess whether the company’s transition to AI‑enabled solutions and bioprocessing platforms is translating into sustained growth and profitability. Analysts and investors will be watching for year‑over‑year revenue trends, gross‑margin performance, and any guidance that reflects the company’s outlook on demand and cost dynamics.
The investor conference call will be held on November 20, 2025, at 11:00 a.m. Eastern Time. A replay of the call will be available through November 27, 2025, and participants can access the session via the company’s Investor Relations website or a live webcast.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.